Association of interleukin-6 - 174G/C promoter polymorphism with hypertension and left ventricular hypertrophy in dialysis patients

Kidney International

Volumn 64, Issue 2, 2003, Pages 616-622

  Losito, Attilio ^a   Kalidas, Kamini ^a   Santoni, Stefania ^a   Jeffery, Steve ^a  

^a NONE

Author keywords

End stage renal disease; Hypertension; Polymorphism

Indexed keywords

CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CX3CR1; INTERLEUKIN 6; UNCLASSIFIED DRUG;

ADULT; AGED; ARTERIAL PRESSURE; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; ELECTROCARDIOGRAM; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEMODIALYSIS; HUMAN; HYPERTENSION; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; OPEN READING FRAME; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

EID: 0038119501     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2003.00119.x     Document Type: Article

References (40)

1. DINARELLO CA, WOLFF SM: The role of interleukin-1 in disease. N Engl J Med 328:106-113, 1993
2. IKONOMIDIS I, ANDREOTTI F, ECONOMOU E, et al: Increased pro-inflammatory cytokines in patients with chronic stable angina and their reduction by aspirin. Circulation 100:793-798, 1999
3. HERBELIN A, URENA P, NGUYE AT, et al: Elevated circulating levels of interleukin-6 in patients with chronic renal failure. Kidney Int 39:954-960, 1991
4. FISHMAN D, FAULDS G, JEFFERY R, et al: The effect of novel polymorphisms in the interleukin-6 (IL-6) gene: Their effect on IL-6 transcription and plasma IL-6 levels and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 102:1369-1376, 1998
5. HUMPHRIES SE, LUONG LA, OGG MS, et al: The interleukin-6 174 G/C polymorphism is associated with risk of coronary heart disease and systolic blood pressure in healthy men. Eur Heart J 22:2219-2220, 2001
6. MOATII D, FAURE S, FUMERON F, et al: Polymorphysm in the fraktalkine receptor CX3CR1 as a genetic risk factor for coronary artery disease. Blood 97:1925-1928, 2001
7. BECKER BN, HIMMELFARB J, HEINRICH WL, et al: Reassessing the cardiac risk profile in chronic hemodialysis patients: A hypothesis on the role of oxidant stress and other non-traditional cardiac risk factors. J Am Soc Nephrol 8:475-486, 1997
8. WANNER C, ZIMMERMANN J, SHWEDLER S, METZGER T: Inflammation and cardiovascular risk in dialysis patients. Kidney Int 61 (Suppl 80):S99-S102, 2002
9. MIDDLETON RJ, PARFREY PS, FOLEY RN: Left ventricular hypertrophy in the renal patient. J Am Soc Nephrol 12:1079-1084, 2001
10. AMERICAN SOCIETY OF HYPERTENSION: Recommendations for routine blood pressure measurement by indirect cuff sphygmomanometry. Am J Hypertens 5:207-209, 1992
11. JOINT NATIONAL COMMITTE ON DETECTION: Evaluation, and treatment of high blood pressure. The sixth report. Arch Intern Med 157:2413-2446, 1997
12. BLACKBURN H, KEYS A, SIMONSON E, et al: The electrocardiogram in population studies. A classification system. Circulation 21:1160-1175, 1960
13. SAHN DJ, DEMARIA A, KISSLO J, WEYMAN A: The committee on M-mode standardization of the American Society of Echocardiography: Recommendations regarding quantitation in M-mode echocardiography: Results of a survey of echocardiographic measurements. Circulation 58:1072-1083, 1978
14. DEVEREUX B, ALONSO DR, LUTAS EM, et al: Echocardiographic assessment of left ventricular hypertrophy: Comparison to necropsy findings. Am J Cardiol 57:450-458, 1986
15. CHERTOW GM, LAZARUS JM, LEW NL, et al: Development of population-specific regression equation to estimate total body water in hemodialysis patients. Kidney Int 51:1578-1582, 1997
16. DAUGIRDAS JT: Second generation logarithmic estimates of single-pool variable volume Kt/V: An analysis of error. J Am Soc Nephrol 4:1205-1213, 1993
17. NATIONAL KIDNEY FOUNDATION: K/DOQI Clinical Practice Guidelines for Hemodialysis Adequacy, 2000. Am J Kidney Dis 37(Suppl 1): S7-864, 2001
18. PIGGOT R, DILLON LP, HEMMINGWAY IH, GEARING AJ: Soluble forms of E-selectin, ICAM-1 and VCAM-1 are present in the supernatant of cytokine activated cultured endothelial cells. Biochem Biophys Res Commun 187:584-589, 1992
19. STENVINKEL P, HEIMBÜRGER O, JOGESTRAND T: Elevated interleukin-6 predicts progressive carotid artery atherosclerosis in dialysis patients: Association with Chlamydia pneumoniae seropositivity. Am J Kidney Dis 39:274-282, 2002
20. CHAE CU, LEE RT, RIFAI N, RIDKER PM: Blood pressure and inflammation in apparently healthy men. Blood Hypertens 38:399-403, 2001
21. PEREIRA BJG, SHAPIRO L, KING AJ, et al: plasma levels of IL-1β, TNF-α, and their specific inhibitors in undialyzed chronic renal failure, CAPD, and hemodialysis patients. Kidney Int 45:890-896, 1994
22. KIMMEL PL, PHILLIPS TM, SIMMENS SJ, et al: Immunological function and survival in hemodialysis patients. Kidney Int 54:236-244, 1998
23. VAZIRI ND, KAUPKE CJ, YOUSEFI S, et al: Cytokine levels during hemodialysis. ASAIO Trans 37:M389-M391, 1991
24. GIRNDT M, SESTER U, KAUL H, KÖHLER H: Production of pro-inflammatory and regulatory monokines in hemodialysis patients shown at single-cell level. J Am Soc Nephrol 9:1689-1696, 1998
25. FISHMAN D, FAULDS G, JEFFERY R, et al: The effect of novel polymorphisms in the interleukin-6 (Il-6) gene on IL-6 transcription and plasma IL-6 levels, and association with systemic-onset juvenile chronic arthritis. J Clin Invest 102:1369-1376, 1998
26. BRULL DJ, MONTGOMERY HE, SANDERS J, DHAMRAIT S, et al: Interleukin-6 gene -174 G/C promoter polymorphisms are strong predictors of plasma interleukin-6 levels after coronary artery bypass surgery. Arterioscler Thromb Vasc Biol 21:1458-1463, 2001
27. VICKERS MA, GREEN FR, TERRY C, et al: Genotype at a promoter polymorphism of the interleukin-6 gene is associated with baseline levels of plasma C-reactive protein. Cardiovasc Res 53:1029-1034, 2002
28. PAPANICOALAOU DA, PETRIDES JS, TSIGOS C, et al: Exercise stimulates interleukin-6 secretion: Inhibition by glucocorticoids and correlation with cathecolamines. Am J Physiol 271:E601-E605, 1996
29. G-nitro-L-arginine methyl ester-induced hypertension. Hypertension 36:103-109, 2000
30. FERNANDEZ-REAL JM, VAYREDA M, RICHART C, et al: Circulating interleukin 6 levels, blood pressure, and insulin sensitivity in apparently healthy men and women. J Clin Endocrinol Metab 86:1154-1159, 2001
31. ZOCCALI C, BENEDETTO FA, MALLAMACI F, et al: Inflammation is associated with carotid atherosclerosis in dialysis patients. Creed Investigators: Cardiovascular Risk Extended Evaluation in Dialysis Patients. J Hypertens 18:1207-1213, 2001
32. BLACHER J, DEMUTH K, GUERIN AP, et al: Association between plasma homocysteine concentration and cardiac hypertrophy in end stage renal disease. J Nephrol 12:248-255, 1999
33. PERTICONE F, MAIO R, CERAVOLO R, et al: Relationship between left ventricular mass and endothelium-dependent vasodilation in never-treated hypertensive patients. Circulation 99:1991-1996, 1999
34. BOLOGA RM, LEVINE DM, PARKER TS, et al: Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia and mortality in hemodialysis patients. Am J Kidney Dis 32:107-114, 1998
35. ELHAGE R, CLAMENS S, BESNARD S, et al: Involvment of interleukin-6 in atherosclerosis but not in the prevention of fatty streak formation by 17-beta-etradiol in apoliprotein E-deficient mice. Atherosclerosis 156:315-320, 2001
36. HIROTA H, YOSHIDA K, KISHIMOTO T, TAGA T: Continuous activation of gp 130, a signal-transducing receptor component for interleukin-6 related cytokines, causes myocardial hypertrophy in mice. Proc Natl Acad Sci USA 92:4862-4866, 1995
37. PENNICA D, KINK KL, SHAW KJ, et al: Expression cloning of cardiotrophin 1, a cytokine that induces cardiac hypertrophy. Proc Natl Acad Sci USA 92:1142-1146, 1995
38. RAURAMAA R, VÄISÄNEN SB, LUONG LA, et al: Stromelysin-1 and interleukin-6 gene promoter polymorphisms are determinants of asymptomatic carotid artery atherosclerosis. Arterioscler Thromb Vasc Biol 20:2657-2662, 2000
39. GIRNDT M, KAUL H, SESTER U, et al: Anti-inflammatory interleukin-10 genotype protects dialysis patients from cardiovascular events. Kidney Int 62:949-955, 2002
40. STENVINKEL P, BARANY P, HEIMBÜRGER O, et al: Mortality, malnutrition, and atherosclerosis in ESRD: What is the role of interleukin-6? Kidney Int 61 (Suppl 80):S103-S108, 2002